4.05

3.57% -0.15

Lixte Biotechnology Holdings Inc (LIXT)

Overview News Price History Financials Discussions Forecast Stock Split

Lixte Biotechnology Holdings Inc stock is traded at $4.05, with a volume of 51,925. It is down -3.57% in the last 24 hours and down -14.74% over the past month. Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Previous Close:

$4.20

Open:

$4.12

24h Volume:

51,925

Relative Volume:

0.44

Market Cap:

$25.40M

Revenue:

Net Income/Loss:

$-4.69M

P/E Ratio:

-1.7382

EPS:

-2.33

Net Cash Flow:

$-3.81M

1W Performance:

+0.00%

1M Performance:

-14.74%

6M Performance:

+209.18%

1Y Performance:

+112.04%

1-Day Range:

$4.01

$4.17

1-Week Range:

$4.01

$4.45

52-Week Range:

$0.64

$6.26

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name

Lixte Biotechnology Holdings Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

310 203 2902

Address

433 PLAZA REAL, BOCA RATON

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

LIXT's Discussions on Twitter

Compare LIXT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIXT Lixte Biotechnology Holdings Inc	4.05	26.34M	0	-4.69M	-3.81M	-2.33
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News

Dec 11, 2025

Lixte Biotechnology shareholders approve board nominees and stock plan amendment - Investing.com

Dec 11, 2025

Lixte Biotechnology shareholders approve board nominees and stock plan amendment By Investing.com - Investing.com South Africa

Dec 11, 2025

Lixte Biotechnology Holds Annual Meeting, Approves Key Issues - TipRanks

Dec 11, 2025

Dec 09, 2025

Lixte’s Big Bet: Making Other Cancer Drugs Work Harder - InvestorNews

Dec 09, 2025

Dec 08, 2025

LIXTE (NASDAQ: LIXT) expands oncology platform with LiGHT proton therapy system - Stock Titan

Dec 08, 2025

Dec 06, 2025

Lixte Biotechnology (LIXT) Stock Analysis Report | Financials & Insights - Benzinga

Dec 06, 2025

Meme Stocks: Will Lixte Biotechnology Holdings Inc stock maintain momentum in 2025Quarterly Trade Report & Free Weekly Watchlist of Top Performers - moha.gov.vn

Dec 06, 2025

Dec 05, 2025

Lixte Biotechnology shares slide following purchase of UK-based Liora - MSN

Dec 05, 2025

Is Lixte Biotechnology Holdings Inc. (8640) stock a buy on weaknessWeekly Profit Recap & Fast Entry Momentum Trade Alerts - Newser

Dec 05, 2025

Will Lixte Biotechnology Holdings Inc. stock maintain momentum in 2025Market Trend Summary & Daily Oversold Stock Bounce Ideas - Newser

Dec 05, 2025

Dec 04, 2025

What sentiment indicators say about Lixte Biotechnology Holdings Inc. stockJuly 2025 EndofMonth & Fast Momentum Entry Tips - Newser

Dec 04, 2025

Is Lixte Biotechnology Holdings Inc. (8640) stock undervalued historicallyQuarterly Trade Summary & Real-Time Volume Surge Alerts - Newser

Dec 04, 2025

Can Lixte Biotechnology Holdings Inc. stock deliver consistent earnings growthJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser

Dec 04, 2025

Published on: 2025-12-04 00:03:12 - Newser

Dec 04, 2025

Dec 03, 2025

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Yahoo Finance

Dec 03, 2025

LIXTE (NASDAQ: LIXT) advances LB-100 combos with GSK, Roche and refines long-term strategy - Stock Titan

Dec 03, 2025

Will Lixte Biotechnology Holdings Inc. (8640) stock rise with strong economy2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser

Dec 03, 2025

Nov 27, 2025

There is no doubt that Lixte Biotechnology Holdings Inc (LIXT) ticks all the boxes. - Setenews

Nov 27, 2025

Nov 25, 2025

Lixte Biotechnology Acquires Liora Technologies for Growth - TipRanks

Nov 25, 2025

LIXTE Biotechnology acquires UK-based proton therapy developer Liora By Investing.com - Investing.com Nigeria

Nov 25, 2025

Lixte Biotechnology stock falls after acquiring UK-based Liora By Investing.com - Investing.com

Nov 25, 2025

Lixte Biotechnology stock falls after acquiring UK-based Liora - Investing.com

Nov 25, 2025

LIXTE Biotechnology (LIXT) Expands with Acquisition of Liora Tec - GuruFocus

Nov 25, 2025

LIXTE Biotechnology acquires UK-based proton therapy developer Liora - Investing.com India

Nov 25, 2025

LIXTE Biotechnology Holdings, Inc. Completes Acquisition of Liora Technologies Europe Ltd. to Advance Proton Therapy Treatment for Cancer - Quiver Quantitative

Nov 25, 2025

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment - InvestorNews

Nov 25, 2025

S&P 500, Dow and NASDAQ end day on positive note as Wall Street begins Thanksgiving week on high with boos - The Economic Times

Nov 25, 2025

Nov 24, 2025

Lixte Biotechnology announces $5M equity financing; shares down - MSN

Nov 24, 2025

Nov 23, 2025

Will Upside Catalysts Materialize for Vallabh Steels Limited in YEARGrowth Stock Opportunities & Small Capital Investment Tips - earlytimes.in

Nov 23, 2025

Nov 21, 2025

Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants By Investing.com - Investing.com Australia

Nov 21, 2025

Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants - Investing.com UK

Nov 21, 2025